138 related articles for article (PubMed ID: 37649975)
1. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma.
Chang JW; Huang CJ; Huang WK; Wang YC; Hsieh JJ; Chang YY; Huang YL; Wu CL; Wang YH; Chen SJ; Tan KT; Chen CP; Wu CE
Clin Transl Immunology; 2023; 12(8):e1465. PubMed ID: 37649975
[TBL] [Abstract][Full Text] [Related]
2. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
3. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ; Sinnberg T; Gschwind A; Niessner H; Demidov G; Amaral T; Ossowski S; Bonzheim I; Röcken M; Riess O; Garbe C; Schroeder C; Forschner A
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825510
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
5. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
6. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.
Byeon S; Cho HJ; Jang KT; Kwon M; Lee J; Lee J; Kim ST
ESMO Open; 2021 Feb; 6(1):100002. PubMed ID: 33399091
[TBL] [Abstract][Full Text] [Related]
8. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
Vlachostergios PJ
Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
[TBL] [Abstract][Full Text] [Related]
10. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
11. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
12. Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study.
Inozume T; Namikawa K; Kato H; Yoshikawa S; Kiniwa Y; Yoshino K; Mizuhashi S; Ito T; Takenouchi T; Matsushita S; Fujisawa Y; Matsuzawa T; Sugihara S; Asai J; Kitagawa H; Maekawa T; Isei T; Yasuda M; Yamazaki N; Uhara H; Nakamura Y
J Dermatol Sci; 2023 Apr; 110(1):19-26. PubMed ID: 37045720
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14.
Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
Front Immunol; 2022; 13():725679. PubMed ID: 35844619
[TBL] [Abstract][Full Text] [Related]
15. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
17. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease.
Ohshima S; Ueki Y; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Okabe R; Matsuyama H; Togashi T; Takatsuka S; Takenouchi T; Horii A
Front Surg; 2022; 9():1032626. PubMed ID: 37082097
[TBL] [Abstract][Full Text] [Related]
19. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
[TBL] [Abstract][Full Text] [Related]
20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
